Bristol-Myers Squibb has taken ownership of Celgene's drug.
2 reports, 2 independent
Updated Aug 18
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol-Myers Squibb has taken ownership of Celgene's drug.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.The BMS/Celgene acquisition is facing legal challenges regarding contingent payments and market competition.1 source
Bristol-Myers Squibb now owns Celgene's drug.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Celgene
American biopharmaceutical company
Nothing else this week.
Related events
- Bristol-Myers Squibb and Novo Nordisk are noted as competitors in the healthcare sector.
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- Canadian investors can access U.S. companies, including Bristol-Myers Squibb, via Canadian Deposit Receipts (CDRs).
- AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.
Coverage
Newest first; wire copies grouped- biopharmadive.com
- ACCESS NewswireActuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy Phase 2 study showed a doubling of the survival rate of metastatic pancreatic cancer patients at Year 1,